Conclusion: HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with ...
We report the results of a retrospective international collaborative study on patients who underwent HSCT for CD40L deficiency between 1993 and 2015, reported ...
CONCLUSION: HSCT is curative in CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS and ...
HSCT is curative in patients with CD40L deficiency, with improved outcome if performed before organ damage development. MAC is associated with better OS, EFS, ...
Jun 24, 2022 · In summary, HSCT using X-linked carriers seems to be safe and results in excellent humoral and cellular immune reconstitution in patients with ...
Jun 24, 2019 · Results: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT.
People also ask
How do you treat CD40 ligand deficiency?
What is the success rate of hematopoietic stem cell transplant?
What are the side effects of hematopoietic stem cell transplantation?
What disease is associated with mutations of the gene encoding the CD40 ligand CD40L and what is the phenotype associated with this disease?
Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an. EBMT/ESID-IEWP-SCETIDE-PIDTC Study. Francesca Ferrua, MD, Stefania ...
Jun 1, 2019 · RESULTS: Overall survival (OS), event-free survival (EFS), and disease-free survival (DFS) were 78.2%, 58.1%, and 72.3% 5 years after HSCT.
CD40 ligand (CD40L) deficiency, an X-linked primary immunodeficiency, causes recurrent sinopulmonary, Pneumocystis and Cryptosporidium species infections.
Hematopoietic stem cell transplantation for CD40 ligand deficiency: Results from an EBMT/ESID-IEWP-SCETIDE-PIDTC study ... Authors: Francesca Ferrua; Stefania ...